A 2025 clinical guideline from the US Departments of Veterans Affairs and Defense strongly recommends cognitive behavioral therapy for insomnia (CBT-I) for chronic insomnia disorder and weakly favors it over medication as first-line care. The 2023 European insomnia guideline also recommends CBT-I first for adults of any age, including those with other medical or psychiatric conditions.

CBT-I is a structured treatment rather than another name for sleep hygiene. It combines changes to sleep timing and bed use with cognitive work, relaxation and sleep education; the European guideline says medication can be offered when CBT-I is not sufficiently effective.

Urgent mental-health symptoms take priority over insomnia treatment

England's National Health Service (NHS) says hallucinations require medical help and calls for emergency care when a person wants to harm themselves or someone else, hears voices directing harm, becomes very agitated, has rapidly worsening hallucinations or suddenly becomes confused. In other countries, the local emergency number or nearest emergency department is the appropriate route.

The 2025 US guideline says CBT-I may need to be delayed for current suicidal ideation or acute mental-health symptoms. A routine insomnia program should wait until immediate safety and acute symptoms have been assessed.

Chronic insomnia is a diagnosis, not a run of bad nights

The 2025 US guideline defines chronic insomnia disorder as sleep difficulty at least three times a week for more than three months, with daytime consequences despite an adequate opportunity to sleep. It also says diagnosis requires a clinical evaluation rather than a questionnaire score alone.

The European guideline calls for a clinical interview covering sleep and medical history, supported by sleep diaries and questionnaires, with a physical examination and other measures when indicated. It reserves overnight sleep testing for suspected additional sleep disorders, treatment-resistant insomnia or other clinical indications rather than routine evaluation.

CBT-I combines five forms of work

In 2023, the World Sleep Society endorsed multicomponent CBT-I as the treatment of choice for chronic insomnia in adults and conditionally endorsed stimulus control, sleep restriction and relaxation as separate therapies. The endorsement did not support sleep-hygiene education as a treatment on its own because evidence for that use was insufficient.

Stimulus control strengthens the bed as a cue for sleep rather than wakefulness and establishes consistent sleep patterns. Sleep restriction therapy initially limits time in bed to actual sleep duration and extends it as sleep efficiency improves.

Cognitive restructuring addresses racing thoughts and inaccurate beliefs about sleep by challenging unhelpful thoughts. Relaxation or counter-arousal strategies reduce physical activation, while sleep-hygiene education addresses light, noise, eating, caffeine, nicotine and alcohol around bedtime.

The five elements are adjusted as a package rather than applied as a fixed checklist. The 2025 US guideline describes CBT-I as a multi-session treatment and says sleep diaries help providers estimate and adjust a sleep schedule. The World Sleep Society did not endorse sleep-hygiene education as a treatment on its own.

A person puts a phone aside in a dim bedroom before sleep (illustrative image)

Comparative evidence favors starting with CBT-I, with limits

A 2024 systematic review and network meta-analysis combined 13 trials involving 823 randomized adults who were not taking hypnotic medicines when enrolled. At a median follow-up of 24 weeks, the odds of remission were higher after starting with CBT-I than after starting with pharmacotherapy, with an odds ratio of 1.82 and a 95 percent confidence interval of 1.15 to 2.87.

The review estimated long-term remission in 41 percent of participants starting with CBT-I and 28 percent starting with pharmacotherapy. Those figures describe the included trials, not a guaranteed outcome, and they do not compare every medicine, treatment combination or patient group.

The 2025 US guideline grades its overall recommendation for CBT-I as strong, but its preference for CBT-I over medication as first-line treatment is weak. The recommendations establish a treatment sequence for clinicians; they do not determine whether an individual prescription should change.

Sleep restriction can temporarily worsen daytime function

The 2025 US guideline reports temporary sleepiness from the sleep-restriction component and says trained professionals should deliver CBT-I to reduce related risks. England's NHS advises people not to drive when sleepy, and the same safety concern applies to other tasks in which reduced alertness could cause harm.

The US guideline lists unstable medical conditions, excessive daytime sleepiness, nighttime fall risk, uncontrolled seizure disorders, bipolar disorder, pregnancy or postpartum insomnia, and acute mental-health symptoms as reasons to adapt or delay CBT-I. These factors do not rule out treatment in every case, but they require an individualized plan.

The World Sleep Society endorsement concerns adults with chronic insomnia, so it does not establish an adult sleep-restriction schedule for children or adolescents. Pediatric sleep problems require a separate clinical assessment rather than a copied adult protocol.

England's NHS notes that many medicines can contribute to insomnia and advises checking with a doctor before taking a sleep aid. Regular prescriptions and nonprescription products should be reviewed with a clinician or pharmacist before any sleep-related medicine change, while availability and regulatory status vary by country.

Delivery can be in person or digital, but access is uneven

The European guideline recommends either in-person or digital CBT-I. The World Sleep Society says individual, in-person CBT-I from a trained professional remains the optimal delivery method while provider training and access vary internationally.

Primary care services, sleep clinics and qualified mental-health professionals may be able to assess local options. APPI News could not verify a single global credential or provider directory at the time of writing, so credentials and referral routes need to be checked in the country where care is delivered.